Application of phenolic acid compounds in preparation of bleeding stopping and stasis eliminating medicaments

A technology for hemostasis and blood stasis, compound, applied in the direction of active ingredients of hydroxyl compounds, drug combinations, blood diseases, etc., can solve problems that have not yet been involved in procoagulation, no raw materials used alone or in combination

Inactive Publication Date: 2011-10-12
GUANGXI UNIV
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Modern epidemiological studies have shown that the intake of phenolic acid active substances by the human body can prevent diseases such as cardiovascular disease, stroke and cancer. Therefore, the current research on it at home and abroad mainly focuses on anticoagulant effects, and has not yet involved procoagulant effects. There are no relevant reports on the use of it alone or in combination as raw materials

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of phenolic acid compounds in preparation of bleeding stopping and stasis eliminating medicaments
  • Application of phenolic acid compounds in preparation of bleeding stopping and stasis eliminating medicaments
  • Application of phenolic acid compounds in preparation of bleeding stopping and stasis eliminating medicaments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example One Chlorogenic Acid, Determination of Bleeding Time (CT) in Mice with p-coumaric Acid

[0022] A group of healthy Kunming mice weighing 18±2g were used for both sexes. Chlorogenic acid and p-coumaric acid were dissolved in distilled water. The experimental mice were divided into 4 groups, 8 mice in each group, administered by intragastric administration for three consecutive days, and the dose was 0.1ml / 10g. The control group was replaced by normal saline, and the positive control group was replaced by Zhixuemin (0.25g / kg). One hour after the last administration, blood was taken from the venous plexus of the mouse medial canthus with a glass capillary (1×12 cm). When the blood filled the capillary, a drop of blood with a diameter of about 5 mm was dropped on the glass slide, and two stopwatches were used to start immediately. timing. After 30s, use the needle to stir slightly from the edge of the blood, carefully observe whether there are blood streaks stirr...

Embodiment 2

[0027] Example 2 Effects of vanillic acid, syringic acid, p-coumaric acid, and protocatechuic acid on rabbit plasma prothrombin time (PT) and partial thromboplastin time (APTT)

[0028] The experimental rabbits were divided into a treatment group and a blank control group. Vanillic acid, syringic acid, p-coumaric acid, and protocatechuic acid were orally administered three days in advance, and blood was drawn one hour after the administration on the third day. Preparation of platelet-free plasma: draw 1.8ml of venous blood, slowly inject it into a plastic test tube containing 0.2ml of 109mmol / L sodium citrate solution, mix well, and centrifuge at 3000r / min for 15min to remove platelets and separate plasma. Take another plastic test tube, add 0.1ml of plasma to be tested, and place it in a 37°C water bath to pre-warm for 3 minutes. Add 0.1ml of PT reagent preheated to 37°C, time it immediately, and keep tilting the test tube in the water bath to mix, and slowly tilt the test tu...

Embodiment 3

[0034] Example 3 Effects of vanillic acid, p-coumaric acid and protocatechuic acid on rabbit platelet aggregation

[0035] Preparation of platelet rich plasma (platelet rich plasma, PRP) and platelet poor plasma (platelet poor plasma, PPP): blood was collected from the carotid artery of conscious rabbits, anticoagulated with 3.8% sodium citrate, collected in plastic test tubes, and blood was mixed with Anticoagulant volume ratio 9:1. After centrifugation at room temperature for 10 minutes at 1200r / min, the obtained plasma is PRP; the remaining blood is then centrifuged at 3000r / min for 15min, and the supernatant is PPP, which is used for zero adjustment during measurement or for adjusting the number of platelets in PRP. During the test, the number of platelets in PRP was controlled at about 500,000 mm -3 .

[0036]Take the measurement tube (put 1 stirring bead in advance), add 200 μl of PPP, place the measurement tube in the preheating hole of the constant temperature body f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a phenolic acid compounds in preparation of bleeding stopping and stasis eliminating medicaments. The phenolic acid compounds mainly comprise chlorogenic acid, caffeic acid, coumaricacid, vanillic acid, cinnamic acid, syringic acid, protocatechuric acid, gallic acid, ferulic acid, p-hydroxybenzoic acid, hydroquinone or pyrocatechol and medicinal salts thereof. Experiments show that the phenolic acid compounds have the functions of stopping blood and eliminating stasis; one or more of the active ingredients is applied to preparing the bleeding stopping and stasis eliminating medicaments which are used for preventing and treating menorrhagia, artificial abortion, postpartum hemorrhage and dysfunctional uterine bleeding of women.

Description

technical field [0001] The invention relates to the medical field of hemostasis and blood stasis removal, in particular to the application of phenolic acid compounds in the preparation of hemostasis and blood stasis medicines. Background technique [0002] Commonly used hemostatic drugs can be divided into three types according to their mechanism of action: the first type is drugs that improve and promote the activity of coagulation factors, commonly used are vitamin K1 and hemostatic; the second type is drugs that directly act on blood vessels, commonly used are Anluo blood and vasopressin; the third is anti-fibrinolytic drugs, commonly used are 6-aminocaproic acid and anti-fibrinolytic aromatic acid (aminomethylbenzoic acid). [0003] Menorrhagia and postpartum hemorrhage are common clinical problems. Menorrhagia accounts for 12% of gynecological diseases (incidence gradually increases with age), and the probability of requiring hysterectomy in the following 5 years is 60...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61K31/192A61K31/05A61P7/04A61P15/00
Inventor 林翠梧黄丽蒙法燕蒋柄丽
Owner GUANGXI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap